Predicting Ocular Drug Behavior with PBPK Modeling
Learn how PBPK modeling predicts ocular drug exposure and target occupancy to optimize anti-VEGF therapies…
CertaraMay 12, 2026
Advancing In Vivo CAR-T with QSP
Learn how QSP modeling improves first-in-human dose selection for CAR-T therapies, enabling better translation and…
CertaraMay 12, 2026
Certara IQ™ Demo
Watch a short demo of Certara IQ™, a QSP platform for modeling, simulation, and analysis.…
CertaraMay 12, 2026
BioSpace webinar: Streamlining Nonclinical Development with FDA NAMs
Learn how to apply FDA NAM guidance to streamline nonclinical development, support IND decisions, and…
CertaraMay 8, 2026
Designing Drug Development Programs for Reimbursement Success
Download the guide to learn how model-informed drug development, QSP, and MBMA help align with…
CertaraMay 7, 2026
Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome
Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome
A newly approved RNA interference (RNAi) therapy lowers harmful triglyceride (TG) levels in patients with…
CertaraMay 7, 2026
Population Pharmacokinetics and Exposure-Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation
This study evaluated how the leukemia drug ziftomenib behaves in the body and whether different…
CertaraMay 7, 2026
Population Pharmacokinetic Modeling and Exposure-Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies
Population pharmacokinetic (PopPK) and exposure-response modeling were used to support the clinical development of nemtabrutinib,…
CertaraMay 7, 2026
